FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

May 19, 2017
by Alejandra Spangler

The FDA has now approved Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients who are cisplatin-ineligible diagnosed with locally advanced or metastatic urothelial carcinoma. Additionally, second-line treatment in patients who are platinum-ineligible and have disease progression during or following chemotherapy or within 12 months of neoadjuvant or adjuvant treatment has also been approved.  KEYTRUDA is the only Anti-PD-1 therapy showing superior overall survival compared to chemotherapy in patients with advanced urothelial carcinoma following platinum failure. Click below to read Merck’s Press Release: Merck Press Release Share this page:

Read More...

Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 Meeting

May 17, 2017
by Alejandra Spangler

On Sunday, May 14th, at the American Urological Association (AUA) 2017 Meeting in Boston, MA, Photocure ASA announced the latest data from their Phase 3 study with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview®. This study showed that in 21.5% of the patients undergoing surveillance cystoscopy, a bladder cancer recurrence would have been missed using only white light as opposed to BLFC with Cysview. This is truly an important development in being able to detect a cancer with a 50-80% recurrence rate. “This study shows that BLFC can provide a significant advantage for patients in terms of early detection of…

Read More...

Marilu Henner Encourages Tough Talks on Bladder Cancer

May 17, 2017
by Stephanie Chisolm

For Bladder Cancer Awareness Month, BCAN and actress Marilu Henner have partnered with Genentech, a member of the Roche group, to share her personal story and help people navigate challenging – but necessary – conversations about bladder cancer. Marilu knows firsthand the importance of these discussions. In 2003, she and her now husband Michael Brown were on vacation when she learned he had blood in his urine. Michael had told his urologist about this symptom before Marilu knew about it, but the urologist told him it was nothing to worry about. “I am incredibly dedicated to my health and the…

Read More...

New Guidelines for Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer!

May 12, 2017
by Stephanie Chisolm

For the first time for any type of malignancy, the American Urological Association (AUA), the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) have formulated an evidence-based guideline for the treatment of non-metastatic muscle-invasive bladder cancer. BCAN Co-Founder, Diane Z. Quale represented patients on the panel of experts that recognized the importance of multidisciplinary collaborative efforts that take into account survival and quality-of-life (QOL) concerns, as they developed the guidelines. Read the new guidelines below: AUA/ASCO/ASTRO/SUO Guideline Share this page:

Read More...

FDA Approves PD-L1 Inhibitor Avelumab (BAVENCIO) for Bladder Cancer

May 9, 2017
by Alejandra Spangler

The PD-L1 inhibitor avelumab (BAVENCIO) has been granted accelerated approval by the Food and Drug Administration. This treatment by Pfizer, Inc. and EMD Serono is targeted to patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. “Until recently, there had been limited innovation in urothelial carcinoma, and this approval gives us another treatment to help battle this aggressive disease.” – Andrea Apolo, MD, medical oncologist at the National Cancer Institute and member of our Scientific Advisory Board Click below to read EMD Serono’s Press Release…

Read More...

FDA accelerates approval of IMFINZI (durvalumab)

May 3, 2017
by Alejandra Spangler

The Food and Drug Administration grants an accelerated approval of IMFINZI (durvalumab), a breakthrough therapy for previously treated advanced bladder cancer patients. This therapy focuses on identifying and attacking cancer cells by restoring the immune system.  This is AstraZeneca’s first approved Immuno-Oncology (IO) therapy.   “We are excited to offer Imfinzi as a breakthrough therapy for patients with locally-advanced or metastatic bladder cancer. Imfinzi is the cornerstone of our extensive Immuno-Oncology programme, in development across many tumour types, as monotherapy and in combination. This first approval for Imfinzi is an important milestone in our return to growth and brings us another step closer…

Read More...

TURBT is Important

April 20, 2017
by Stephanie Chisolm

URO Today article notes that the precise and thorough resection (TURBT) of all existing tumors remains a critical factor influencing bladder cancer patient outcomes. It can not only reduce the incidence of under-staging, but also can provide the optimal setting for adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.) Enhanced cystoscopy has a critical role to play in helping urologists in this area, as recommended by the updated AUA/SUO guidelines on NMIBC.   Read the article by BCAN Scientific Advisory Board member Ashish Kamat, MD and Kamal Pohar, MD here. Share this page:

Read More...

Great news! Expanding options in immunotherapy

April 18, 2017
by Stephanie Chisolm

The FDA Granted Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer. “It is encouraging to see continued progress in the treatment of advanced bladder cancer, which until last year had not seen any major advancements in more than 30 years,” said Andrea Maddox Smith, chief executive officer, Bladder Cancer Advocacy Network. “We are excited that TECENTRIQ is now a treatment option for people with advanced bladder cancer who are unable to receive a cisplatin-based chemotherapy as an initial treatment.” Read more. Share this page:

Read More...

Get ready for this May’s National Bladder Cancer Awareness Month!

March 30, 2017
by Alejandra Spangler

BCAN is getting amped up for May 2017’s National Bladder Cancer Awareness Month. Join us by checking out our new Communications Toolkit and putting to use the multiple resources available. This year we urge you to “Own Your Health and Have an Impact” by raising awareness about the risks, signs & symptoms of bladder cancer, the 5th most common cancer in the US.  Click below to learn more about our Communications Toolkit!   Communications Toolkit     Share this page:

Read More...

BCAN Launches My Bladder Cancer Story

February 21, 2017
by Stephanie Chisolm

This year, over 79,000 people will be diagnosed with bladder cancer. BCAN understands that there are real people behind this number. Our ‘My Bladder Cancer Story’ Campaign presents stories to raise awareness and call attention to the lives and daily experiences of bladder cancer patients and families nationwide. Read the stories            Share your Story Share this page:

Read More...